A DECISION to block a cancer drug being prescribed on the NHS is to be reviewed.
The National Institute for Health and Clinical Excellence said it would reconsider its ban on Azacitidine – used to treat a range of bone marrow disorders.
The drug gives some sufferers a few extra months of life.Mike Hobday, from Macmillan Cancer Support, said: “We are pleased by NICE’s decision to review the use of Azacitidine.
“Patients with myelodyplastic syndrome, chronic myelomonocytic leukaemia, and acute myeloid leukaemia have very few treatment options and this drug could give them more time and a better quality of life.
“Everyone should get the drugs their doctor recommends, regardless of what type of cancer they have, or where they live and should not be penalised because of the type of cancer they have. Although a few extra weeks or months might not sound much to some people it can mean an awful lot to a family affected by cancer.”
For more information and to see comments about this report click HERE to visit the Daily Express website.